The Clinical Problem Solvers
JANUARY 18, 2021
Understand that collective action and a focus on community, rather than individualism, are most effective in combating racism and achieving health equity. One of the biggest barriers to health equity is the narrow focus on the individual and a failure to see health as a widespread community issue.
FDA Law Blog
OCTOBER 9, 2022
The president’s first step was a pardon of all prior federal offenses of simple marijuana possession and a direction to the Attorney General to develop an administrative process to issue certificates of pardon to eligible individuals. HHS has undertaken scientific and medical evaluations of marijuana in recent years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
MARCH 7, 2024
Sasinowski — In 2009 — 15 years ago — the National Organization for Rare Disorders (NORD) announced the first U.S. In 2009 I served as Chair of NORD and through the hard work of countless colleagues we inaugurated the first Rare Disease Day. By Frank J. recognition of Rare Disease Day.
FDA Law Blog
AUGUST 2, 2022
Within the last month, the Cannabis Regulators of Color Coalition (“CRCC”) and handful of Democratic Senators have separately reached out to Biden Administration officials, including Attorney General Merrick Garland, requesting action to mitigate or eliminate federal prohibition on the use of cannabis. 21 U.S.C. § 812(b)(1). 26, 2022).
The Clinical Problem Solvers
DECEMBER 16, 2020
Moreover, center patients not only in discussions about individual decision-making but in constructing and drawing meaning from the research. Tsai has seen race-based medicine play out in clinical practice 10:45 What role should race play in making clinical decisions?
GeriPal
OCTOBER 13, 2022
And so there was a report in 2009 by the Institute of Medicine saying that we need to equip all of these individuals in caring for older person in an evidence based manner. When I’m on service these days there is inevitably a moment when a resident says “Patient so-and-so is on X” – and I have absolutely no idea what X is.
FDA Law Blog
FEBRUARY 27, 2024
Consequently, because both applications were approved at the same time, both applications represent the first permitted commercial marketing or use of the product or the individual active ingredients, as outlined under 35 U.S.C. leave you scratching your head (we’ll call it “Who’s Buried in Grant’s Tomb?”). l 56(c)(4) and 37 C.F.R.
Expert insights. Personalized for you.
52 
Let's personalize your content